Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization

Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design

“…This might be attributed to poloxamer 188, a nonionic surfactant which decreases the electrostatic repulsion between the particles and sterically stabilizes the nanoparticles by forming a coat around their surface. 28 The negative charge of SLN may result from fatty acids released from the hydrolysis of GMS. In such a system, the hydrophilic emulsifiers were thought to align alongside each other, imparting more rigidity and strength to the emulsifier film through hydrogen bonding.…”

Lipid Nanoparticulate Drug Delivery Systems: A Revolution in Dosage Form Design and Development

“…High pressure homogenisation (HPH) is a suitable method for the preparation of SLN, NLC and LDC-nanoparticles and can be performed at elevated temperature (hot HPH technique) or at and below room temperature (cold HPH technique) [11,55]. The particle size is decreased by impact, shear, cavitation and turbulence.…”

“…Only highly potent low dose hydrophilic drugs may be suitably incorporated in the solid lipid matrix [11]. In order to overcome this limitation, LDC nanoparticles with drug loading capacities of up to 33% were developed [8].…”

Nano-based drug delivery system

“…In general, SLNs have a circular shape and an average 100-500 nm diameter and so drug release is controlled and sustained over a long period. Drug release from solid lipid nanoparticles produced by the hot homogenization method is faster than from those produced by cold homogenization [307,308]. Drug release studies are generally carried out using UV-VIS spectrometry or HPLC.…”